Publicacións en colaboración con investigadores/as de University of Washington School of Medicine (4)

2020

  1. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

    ACR Open Rheumatology, Vol. 2, Núm. 8, pp. 459-470

2018

  1. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: A pooled analysis of the PALACE 1-3 studies

    RMD Open, Vol. 4, Núm. 1

2015

  1. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

    Journal of Rheumatology, Vol. 42, Núm. 3, pp. 479-488

2014

  1. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026